Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

February 18 2021Regulatory
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the fourth quarter and full year ended December 31,

February 2 2021Regulatory
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces positive Phase 2

January 14 2021Regulatory
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Top-line results expected in 2Q 2021 LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it has completed enrollment (n=45) in its pilot clinical study

January 5 2021Regulatory
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the

November 23 2020Regulatory
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank

Non-dilutive capital to provide further financial flexibility LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it has entered

November 9 2020Regulatory
Verona Pharma Announces November 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2021. All rights reserved